Sign In
Buy GTBP
$0.439
-0.0279 (-5.97%)
At Close: Jun 03, 2026
GT Biopharma to Participate in the H.C. Wainwright Cell Therapy Virtual Conference
09:00am, Friday, 24'th Feb 2023
BRISBANE, CALIFORNIA, Feb. 24, 2023 (GLOBE NEWSWIRE) -- GT Biopharma, Inc. (NASDAQ: GTBP), a clinical stage immuno-oncology company focused on developing innovative therapeutics based on the Company's
GT Biopharma to Present New Data on Novel Dual-Antigen Targeting Approach Against AML at Upcoming 2022 ASH Annual Meeting
09:30am, Thursday, 03'rd Nov 2022
BRISBANE, CALIFORNIA, Nov. 03, 2022 (GLOBE NEWSWIRE) — GT Biopharma, Inc. (the “Company” or “GTB”) (NASDAQ: GTBP), a clinical stage immuno-oncology company focused on developing innovative t
GT Biopharma Announces Adjournment of Special Shareholders Meeting
04:30pm, Tuesday, 04'th Oct 2022
– Meeting adjourned to October 10, 2022 at 11 a.m. PST– GTB encourages all stockholders of record on August 8, 2022 who have not yet voted– to do so by 11:59 p.m. PST Time on October 9, 2022 BRI
GT Biopharma to Participate in the H.C. Wainwright 24th Annual Global Investment Conference in September
07:30am, Thursday, 08'th Sep 2022
BRISBANE, Calif., Sept. 08, 2022 (GLOBE NEWSWIRE) -- GT Biopharma, Inc. (NASDAQ: GTBP), a clinical stage immuno-oncology company focused on developing innovative therapeutics based on the Company's pr
GT Biopharma to Participate at H.C. Wainwright Hybrid Global Investment Conference
08:00am, Thursday, 12'th May 2022
BRISBANE, Calif., May 12, 2022 (GLOBE NEWSWIRE) -- GT Biopharma, Inc. (NASDAQ: GTBP), an immuno-oncology company focused on developing innovative therapeutics based on the Company's proprietary tri-sp
GT Biopharma to Present Pre-Clinical Data at Upcoming Medical Conferences
07:30am, Thursday, 24'th Feb 2022
BRISBANE, Calif., Feb. 24, 2022 /PRNewswire/ -- GT Biopharma, Inc. (NASDAQ: GTBP), a clinical stage immuno-oncology company focused on developing innovative therapeutics based on the Company's proprie
GT Biopharma names Manu Ohri as CFO
12:44pm, Friday, 18'th Feb 2022 Seeking Alpha
GT Biopharma (GTBP), a clinical-stage immunooncology company, has named Manu Ohri as its Chief Financial Officer ((CFO)) with immediate effect.Ohri has over 25 years of management,…
GT Biopharma to Present at B. Riley Securities' Virtual Oncology Conference
07:30am, Thursday, 20'th Jan 2022
BRISBANE, Calif., Jan. 20, 2022 /PRNewswire/ -- GT Biopharma, Inc. (NASDAQ: GTBP), a clinical stage immuno-oncology company focused on developing innovative therapeutics based on the Company's proprie
State Street Corp Makes New Investment in GT Biopharma, Inc. (OTCMKTS:GTBP)
10:08am, Sunday, 28'th Nov 2021 Dakota Financial News
State Street Corp acquired a new position in shares of GT Biopharma, Inc. (OTCMKTS:GTBP) in the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor acquired 374,704 shares of the company’s stock, valued at approximately $5,808,000. State Street Corp owned about 1.77% of GT Biopharma at […]
GT BioPharma to Host a Management Update Conference Call
09:05pm, Wednesday, 24'th Nov 2021 Business Insider Markets
BEVERLY HILLS, Calif., Nov. 24, 2021 /PRNewswire/ -- GT Biopharma, Inc. (the "Company") (NASDAQ: GTBP), a clinical stage immuno-oncology company focused on developing innovative therapeutics based on the Company''s proprietary natural killer (NK) cell
GT Biopharma (OTCMKTS:GTBP) Downgraded to Sell at Zacks Investment Research
07:50am, Tuesday, 23'rd Nov 2021 Dakota Financial News
Zacks Investment Research downgraded shares of GT Biopharma (OTCMKTS:GTBP) from a hold rating to a sell rating in a research report report published on Monday, Zacks.com reports. According to Zacks, “GT Biopharma Inc. is an immuno-oncology company. It discovers, develops and commercializes drugs of therapeutic molecules for the treatment of cancer, myeloma, osteolytic lesions and […]
GT Biopharma (OTCMKTS:GTBP) Cut to Hold at Zacks Investment Research
09:58am, Wednesday, 17'th Nov 2021 Transcript Daily
Zacks Investment Research cut shares of GT Biopharma (OTCMKTS:GTBP) from a buy rating to a hold rating in a report published on Tuesday, Zacks.com reports. According to Zacks, GT Biopharma Inc. is an immuno-oncology company. It discovers, develops and commercializes drugs of therapeutic molecules for the treatment of cancer, myeloma, osteolytic lesions and other unmet []
GT Biopharma: Shift In Therapy Strategy Reduces Attractiveness
06:44am, Monday, 15'th Nov 2021 Seeking AlphaGT Biopharma: Shift In Therapy Strategy Reduces Attractiveness
01:44am, Monday, 15'th Nov 2021
GT Biopharma: Shift In Therapy Strategy Reduces Attractiveness
Vanguard Group Inc. Boosts Stake in GT Biopharma, Inc. (OTCMKTS:GTBP)
09:20am, Sunday, 14'th Nov 2021 Dakota Financial News
Vanguard Group Inc. increased its holdings in shares of GT Biopharma, Inc. (OTCMKTS:GTBP) by 267.0% in the 2nd quarter, HoldingsChannel reports. The firm owned 982,269 shares of the companys stock after acquiring an additional 714,605 shares during the quarter. Vanguard Group Inc.s holdings in GT Biopharma were worth $15,225,000 as of its most recent filing []
